Reaction
Myelitis reporting signals
As of the last recalculation, Myelitis appears in 1,532 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is BLEOMYCIN SULFATE (PRR 29.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Bleomycin Sulfate | 22 | 29.3 | 29.4 |
| Busulfan | 29 | 25.5 | 25.5 |
| Bupivacaine | 14 | 20.5 | 20.6 |
| Axicabtagene Ciloleucel | 14 | 19.4 | 19.5 |
| Fludarabine Phosphate | 43 | 15.3 | 15.3 |
| Brentuximab Vedotin | 9 | 12.0 | 12.0 |
| Telmisartan | 15 | 11.5 | 11.5 |
| Ifosfamide | 18 | 11.5 | 11.5 |
| Granisetron Hydrochloride | 8 | 10.5 | 10.5 |
| Ofatumumab | 25 | 10.4 | 10.4 |
| Atovaquone | 6 | 10.2 | 10.2 |
| Ipilimumab | 30 | 9.6 | 9.6 |
| Granisetron | 7 | 9.1 | 9.1 |
| Cytarabine | 38 | 8.8 | 8.8 |
| Thiotepa | 6 | 8.6 | 8.6 |
| Micafungin Sodium | 5 | 8.0 | 8.0 |
| Teriflunomide | 25 | 7.6 | 7.6 |
| Cyclophosphamide Injection, Solution | 93 | 7.5 | 7.5 |
| Cyclophosphamide | 93 | 7.5 | 7.5 |
| Cyclophosphamide For Injection | 93 | 7.5 | 7.5 |
| Cladribine | 5 | 7.1 | 7.1 |
| Doxorubicin | 45 | 7.0 | 7.0 |
| Polatuzumab Vedotin | 5 | 7.0 | 7.0 |
| Fingolimod Hcl | 43 | 6.9 | 6.9 |
| Durvalumab | 10 | 6.7 | 6.7 |
| Etoposide | 35 | 6.6 | 6.6 |
| Nivolumab | 42 | 6.0 | 6.0 |
| Ocrelizumab | 27 | 6.0 | 6.0 |
| Atezolizumab | 17 | 6.0 | 6.0 |
| Carboplatin | 52 | 5.7 | 5.7 |
| Interferon Beta-1B | 8 | 5.7 | 5.7 |
| Ravulizumab | 5 | 5.0 | 5.0 |
| Natalizumab | 57 | 4.4 | 4.4 |
| Dimethyl Fumarate | 36 | 4.0 | 4.0 |
| Glatiramer Acetate | 17 | 3.9 | 3.9 |